ArticleContemporary clinical trials2022
Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.
Article in Contemporary clinical trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02135419 (ANCHOR Study), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01).JCO oncology practice · 2025Trial
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.The New England journal of medicine · 2022Trial
- Advancing HIV and Cancer Research: Implementing an AIDS and Cancer Specimen Resource in Latin America.Biopreservation and biobanking · 2025Article
- Strengthening anal cancer prevention in Abuja, Nigeria: Identifying barriers and potential strategies to improve training.PLOS global public health · 2025Article
- Changing the paradigm: Elimination - Not only of cervical cancer.Gynecologic oncology reports · 2024Article
- Deployment and assessment of a deep learning model for real-time detection of anal precancer with high frame rate high-resolution microendoscopy.Scientific reports · 2023Article
- Duration of Time CD4/CD8 Ratio is Below 0.5 is Associated with Progression to Anal Cancer in Patients with HIV and High-Grade Dysplasia.Annals of surgical oncology · 2023Article
- Integration of human papillomavirus associated anal cancer screening into HIV care and treatment program in Pakistan: perceptions of policymakers, managers, and care providers.BMC public health · 2023Article
- Human Papillomavirus Genotypes Infecting the Anal Canal and Cervix in HIV+ Men and Women, Anal Cytology, and Risk Factors for Anal Infection.Pathogens (Basel, Switzerland) · 2023Article
- Anal Cancer in High-Risk Women: The Lost Tribe.Cancers · 2022Review
- Article
- Follow-Up to High-Resolution Anoscopy After Abnormal Anal Cytology in People Living with HIV.AIDS patient care and STDs · 2022Article
- Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model.Journal of cancer science and clinical therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
Abstract
It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV. To address these concerns, the AIDS Malignancy Consortium completed a large-scale, randomized trial to compare strategies for the prevention of anal cancer among PLWH with anal HSIL. The objective of the study was to determine whether treating anal HSIL was effective in reducing the incidence of anal cancer in PLWH compared with active monitoring. This paper describes the design of the ANal Cancer/HSIL Outcomes Research Study (ANCHOR) with respect to estimating the anal cancer event rate in this high risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.